{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T13:53:44Z","timestamp":1791122024221,"version":"4.1.0"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,5,9]],"date-time":"2026-05-09T00:00:00Z","timestamp":1778284800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,5,9]],"date-time":"2026-05-09T00:00:00Z","timestamp":1778284800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100016724","name":"Postgraduate Institute of Medical Education and Research, Chandigarh","doi-asserted-by":"publisher","award":["IM\/194\/18-03-23-0831"],"award-info":[{"award-number":["IM\/194\/18-03-23-0831"]}],"id":[{"id":"10.13039\/100016724","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Divers"],"DOI":"10.1007\/s11030-026-11561-y","type":"journal-article","created":{"date-parts":[[2026,5,9]],"date-time":"2026-05-09T10:12:49Z","timestamp":1778321569000},"page":"8277-8296","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Differential response of HER2\u2009\u2212\u2009and HER2\u2009+\u2009breast cancer cells to quinazoline and triazole derivatives: advancing receptor subtype-specific phytochemical targeting"],"prefix":"10.1007","volume":"30","author":[{"given":"Jitender","family":"Singh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5603-4523","authenticated-orcid":false,"given":"Pramod K.","family":"Avti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krishan L.","family":"Khanduja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Divya","family":"Dahiya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,9]]},"reference":[{"key":"11561_CR1","doi-asserted-by":"publisher","first-page":"412","DOI":"10.5306\/wjco.v5.i3.412","volume":"5","author":"O Yersal","year":"2014","unstructured":"Yersal O (2014) Biological subtypes of breast cancer: Prognostic and therapeutic implications. WJCO 5:412. https:\/\/doi.org\/10.5306\/wjco.v5.i3.412","journal-title":"WJCO"},{"key":"11561_CR2","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1038\/s41523-019-0116-8","volume":"5","author":"P Poudel","year":"2019","unstructured":"Poudel P, Nyamundanda G, Patil Y et al (2019) Heterocellular gene signatures reveal luminal-A breast cancer heterogeneity and differential therapeutic responses. npj Breast Cancer 5:21. https:\/\/doi.org\/10.1038\/s41523-019-0116-8","journal-title":"npj Breast Cancer"},{"key":"11561_CR3","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1016\/j.arcmed.2020.08.001","volume":"51","author":"LP Guido","year":"2020","unstructured":"Guido LP, Gomez-Fernandez C (2020) Advances in the molecular taxonomy of breast cancer. Arch Med Res 51:777\u2013783. https:\/\/doi.org\/10.1016\/j.arcmed.2020.08.001","journal-title":"Arch Med Res"},{"key":"11561_CR4","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.3389\/fonc.2019.01124","volume":"9","author":"A Godoy-Ortiz","year":"2019","unstructured":"Godoy-Ortiz A, Sanchez-Munoz A, Chica Parrado MR et al (2019) Deciphering HER2 breast cancer disease: biological and clinical implications. Front Oncol 9:1124. https:\/\/doi.org\/10.3389\/fonc.2019.01124","journal-title":"Front Oncol"},{"key":"11561_CR5","doi-asserted-by":"publisher","first-page":"59","DOI":"10.5152\/tjbh.2015.1669","volume":"11","author":"N Eliyatkin","year":"2015","unstructured":"Eliyatkin N, Yalcin E, Zengel B et al (2015) Molecular classification of breast carcinoma: from traditional, old-fashioned way to a new age, and a new way. J Breasth Health 11:59\u201366. https:\/\/doi.org\/10.5152\/tjbh.2015.1669","journal-title":"J Breasth Health"},{"key":"11561_CR6","doi-asserted-by":"publisher","first-page":"496","DOI":"10.20892\/j.issn.2095-3941.2016.0066","volume":"13","author":"AS Nahed","year":"2016","unstructured":"Nahed AS, Shaimaa MY (2016) Ki-67 as a prognostic marker according to breast cancer molecular subtype. Cancer Biol Med 13:496. https:\/\/doi.org\/10.20892\/j.issn.2095-3941.2016.0066","journal-title":"Cancer Biol Med"},{"key":"11561_CR7","doi-asserted-by":"publisher","first-page":"173","DOI":"10.3390\/ijms22010173","volume":"22","author":"D Miricescu","year":"2020","unstructured":"Miricescu D, Totan A, Stanescu-Spinu I-I et al (2020) PI3K\/AKT\/mTOR Signaling pathway in breast cancer: from molecular landscape to clinical aspects. IJMS 22:173. https:\/\/doi.org\/10.3390\/ijms22010173","journal-title":"IJMS"},{"key":"11561_CR8","doi-asserted-by":"publisher","first-page":"S57","DOI":"10.1016\/j.breast.2013.07.011","volume":"22","author":"RS Kerbel","year":"2013","unstructured":"Kerbel RS, Guerin E, Francia G et al (2013) Preclinical recapitulation of antiangiogenic drug clinical efficacies using models of early or late stage breast cancer metastatis. The Breast 22:S57\u2013S65. https:\/\/doi.org\/10.1016\/j.breast.2013.07.011","journal-title":"The Breast"},{"key":"11561_CR9","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/s41687-019-0098-1","volume":"3","author":"N Galipeau","year":"2019","unstructured":"Galipeau N, Klooster B, Krohe M et al (2019) Understanding key symptoms, side effects, and impacts of HR+\/HER2\u2009\u2212\u2009advanced breast cancer: qualitative study findings. J Patient Rep Outcomes 3:10. https:\/\/doi.org\/10.1186\/s41687-019-0098-1","journal-title":"J Patient Rep Outcomes"},{"key":"11561_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.mce.2021.111322","volume":"532","author":"F Rasha","year":"2021","unstructured":"Rasha F, Sharma M, Pruitt K (2021) Mechanisms of endocrine therapy resistance in breast cancer. Mol Cell Endocrinol 532:111322. https:\/\/doi.org\/10.1016\/j.mce.2021.111322","journal-title":"Mol Cell Endocrinol"},{"key":"11561_CR11","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1038\/s41573-022-00579-0","volume":"22","author":"SM Swain","year":"2023","unstructured":"Swain SM, Shastry M, Hamilton E (2023) Targeting HER2\u2009\u2212\u2009positive breast cancer: advances and future directions. Nat Rev Drug Discov 22:101\u2013126. https:\/\/doi.org\/10.1038\/s41573-022-00579-0","journal-title":"Nat Rev Drug Discov"},{"key":"11561_CR12","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1038\/s41571-024-00924-9","volume":"21","author":"J Yoon","year":"2024","unstructured":"Yoon J, Oh D-Y (2024) HER2\u2009\u2212\u2009targeted therapies beyond breast cancer\u2014an update. Nat Rev Clin Oncol 21:675\u2013700. https:\/\/doi.org\/10.1038\/s41571-024-00924-9","journal-title":"Nat Rev Clin Oncol"},{"key":"11561_CR13","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1038\/s41523-021-00265-1","volume":"7","author":"I Schlam","year":"2021","unstructured":"Schlam I, Swain SM (2021) HER2\u2009\u2212\u2009positive breast cancer and tyrosine kinase inhibitors: the time is now. npj Breast Cancer 7:56. https:\/\/doi.org\/10.1038\/s41523-021-00265-1","journal-title":"npj Breast Cancer"},{"key":"11561_CR14","doi-asserted-by":"publisher","first-page":"1987","DOI":"10.3390\/cancers15071987","volume":"15","author":"MF Mercogliano","year":"2023","unstructured":"Mercogliano MF, Bruni S, Mauro FL, Schillaci R (2023) Emerging targeted therapies for HER2\u2009\u2212\u2009positive breast cancer. Cancers 15:1987. https:\/\/doi.org\/10.3390\/cancers15071987","journal-title":"Cancers"},{"key":"11561_CR15","doi-asserted-by":"publisher","first-page":"5527","DOI":"10.3390\/cancers13215527","volume":"13","author":"L Brown","year":"2021","unstructured":"Brown L, Meredith T, Yu J et al (2021) Heart failure therapies for the prevention of HER2\u2009\u2212\u2009monoclonal antibody-mediated cardiotoxicity: a systematic review and meta-analysis of randomized trials. Cancers 13:5527. https:\/\/doi.org\/10.3390\/cancers13215527","journal-title":"Cancers"},{"key":"11561_CR16","doi-asserted-by":"publisher","first-page":"423","DOI":"10.2147\/BCTT.S503703","volume":"17","author":"B Rao","year":"2025","unstructured":"Rao B, Huo P, Lu J, Huang W (2025) Advances in targeted therapy for brain metastases in human epidermal growth factor receptor 2 (HER2)-positive breast cancer: a focus on ADCs and TKIs. Breast Cancer (Dove Med Press) 17:423\u2013432. https:\/\/doi.org\/10.2147\/BCTT.S503703","journal-title":"Breast Cancer (Dove Med Press)"},{"key":"11561_CR17","doi-asserted-by":"publisher","first-page":"e859","DOI":"10.1093\/oncolo\/oyad127","volume":"28","author":"C Ji","year":"2023","unstructured":"Ji C, Li F, Yuan Y et al (2023) Novel Anti-HER2 antibody-drug conjugates versus T-DM1 for HER2\u2009\u2212\u2009positive metastatic breast cancer after tyrosine kinase inhibitors treatment. Oncologist 28:e859\u2013e866. https:\/\/doi.org\/10.1093\/oncolo\/oyad127","journal-title":"Oncologist"},{"key":"11561_CR18","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.3390\/cancers15041023","volume":"15","author":"VP Chavda","year":"2023","unstructured":"Chavda VP, Nalla LV, Balar P et al (2023) Advanced phytochemical-based nanocarrier systems for the treatment of breast cancer. Cancers 15:1023. https:\/\/doi.org\/10.3390\/cancers15041023","journal-title":"Cancers"},{"key":"11561_CR19","doi-asserted-by":"publisher","first-page":"zyad014","DOI":"10.1093\/intbio\/zyad014","volume":"15","author":"PK Avti","year":"2023","unstructured":"Avti PK, Singh J, Dahiya D, Khanduja KL (2023) Dual functionality of pyrimidine and flavone in targeting genomic variants of EGFR and ER receptors to influence the differential survival rates in breast cancer patients. Integrative Biol 15:zyad014. https:\/\/doi.org\/10.1093\/intbio\/zyad014","journal-title":"Integrative Biol"},{"key":"11561_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/j.phytochem.2021.113058","volume":"195","author":"R Gaonkar","year":"2022","unstructured":"Gaonkar R, Singh J, Chauhan A et al (2022) Geraniol and Citral as potential therapeutic agents targeting the HSP90 activity: An in silico and experimental approach. Phytochemistry 195:113058. https:\/\/doi.org\/10.1016\/j.phytochem.2021.113058","journal-title":"Phytochemistry"},{"key":"11561_CR21","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1007\/s11010-008-9886-2","volume":"319","author":"KL Khanduja","year":"2008","unstructured":"Khanduja KL, Kumar S, Varma N et al (2008) Enhancement in alpha-tocopherol succinate-induced apoptosis by all-trans-retinoic acid in primary leukemic cells: role of antioxidant defense, Bax and c-myc. Mol Cell Biochem 319:133\u2013139. https:\/\/doi.org\/10.1007\/s11010-008-9886-2","journal-title":"Mol Cell Biochem"},{"key":"11561_CR22","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2025.152404","volume":"778","author":"J Singh","year":"2025","unstructured":"Singh J, Khanduja KL, Avti PK (2025) Flavonoids and nitrogen-containing heterocyclic phytochemicals regulate DNA repair via mir-2909-mediated modulation of MRN-checkpoint genes in breast cancer. Biochem Biophys Res Commun 778:152404. https:\/\/doi.org\/10.1016\/j.bbrc.2025.152404","journal-title":"Biochem Biophys Res Commun"},{"key":"11561_CR23","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1007\/s11010-021-04338-4","volume":"477","author":"J Singh","year":"2022","unstructured":"Singh J, Sangwan N, Chauhan A et al (2022) Screening and identification of phytochemical drug molecules against mutant BRCA1 receptor of breast cancer using computational approaches. Mol Cell Biochem 477:885\u2013896. https:\/\/doi.org\/10.1007\/s11010-021-04338-4","journal-title":"Mol Cell Biochem"},{"key":"11561_CR24","doi-asserted-by":"publisher","first-page":"1548","DOI":"10.1080\/08927022.2022.2107638","volume":"48","author":"J Singh","year":"2022","unstructured":"Singh J, Sangwan N, Chauhan A, Avti PK (2022) Integrative network and computational simulation of clinical and genomic data for the identification of mutated EGFR in breast cancer patients for therapeutic targeting using purine analogues. Mol Simul 48:1548\u20131560. https:\/\/doi.org\/10.1080\/08927022.2022.2107638","journal-title":"Mol Simul"},{"key":"11561_CR25","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1016\/j.biopha.2017.10.124","volume":"97","author":"V Kaur","year":"2018","unstructured":"Kaur V, Kumar M, Kumar A et al (2018) Pharmacotherapeutic potential of phytochemicals: Implications in cancer chemoprevention and future perspectives. Biomed Pharmacother 97:564\u2013586. https:\/\/doi.org\/10.1016\/j.biopha.2017.10.124","journal-title":"Biomed Pharmacother"},{"key":"11561_CR26","doi-asserted-by":"publisher","first-page":"1614","DOI":"10.3389\/fphar.2019.01614","volume":"10","author":"AS Choudhari","year":"2020","unstructured":"Choudhari AS, Mandave PC, Deshpande M et al (2020) Phytochemicals in cancer treatment: from preclinical studies to clinical practice. Front Pharmacol 10:1614. https:\/\/doi.org\/10.3389\/fphar.2019.01614","journal-title":"Front Pharmacol"},{"key":"11561_CR27","doi-asserted-by":"publisher","first-page":"10737","DOI":"10.3390\/ijms241310737","volume":"24","author":"V Marin","year":"2023","unstructured":"Marin V, Burgos V, Perez R et al (2023) The potential role of Epigallocatechin-3-Gallate (EGCG) in breast cancer treatment. IJMS 24:10737. https:\/\/doi.org\/10.3390\/ijms241310737","journal-title":"IJMS"},{"key":"11561_CR28","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1007\/s11010-007-9590-7","volume":"307","author":"S Kumar","year":"2007","unstructured":"Kumar S, Khanduja KL, Verma N et al (2007) ATRA promotes alpha tocopherol succinate-induced apoptosis in freshly isolated leukemic cells from chronic myeloid leukemic patients. Mol Cell Biochem 307:109\u2013119. https:\/\/doi.org\/10.1007\/s11010-007-9590-7","journal-title":"Mol Cell Biochem"},{"key":"11561_CR29","doi-asserted-by":"publisher","first-page":"2733","DOI":"10.1056\/NEJMoa064320","volume":"355","author":"CE Geyer","year":"2006","unstructured":"Geyer CE, Forster J, Lindquist D et al (2006) Lapatinib plus capecitabine for HER2\u2009\u2212\u2009positive advanced breast cancer. N Engl J Med 355:2733\u20132743. https:\/\/doi.org\/10.1056\/NEJMoa064320","journal-title":"N Engl J Med"},{"key":"11561_CR30","doi-asserted-by":"publisher","first-page":"2300641","DOI":"10.1002\/ardp.202300641","volume":"357","author":"J Song","year":"2024","unstructured":"Song J, Zhang S, Zhang B, Ma J (2024) The anti-breast cancer therapeutic potential of 1,2,3-triazole-containing hybrids. Arch Pharm 357:2300641. https:\/\/doi.org\/10.1002\/ardp.202300641","journal-title":"Arch Pharm"},{"key":"11561_CR31","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1016\/j.bioorg.2017.12.013","volume":"76","author":"HAM El-Sherief","year":"2018","unstructured":"El-Sherief HAM, Youssif BGM, Bukhari SNA et al (2018) Novel 1,2,4-triazole derivatives as potential anticancer agents: Design, synthesis, molecular docking and mechanistic studies. Bioorg Chem 76:314\u2013325. https:\/\/doi.org\/10.1016\/j.bioorg.2017.12.013","journal-title":"Bioorg Chem"},{"key":"11561_CR32","doi-asserted-by":"publisher","DOI":"10.1002\/ardp.202300682","volume":"357","author":"YM Syam","year":"2024","unstructured":"Syam YM, Abd El-Karim SS, Abdel-Mohsen HT (2024) Quinazoline-oxindole hybrids as angiokinase inhibitors and anticancer agents: Design, synthesis, biological evaluation, and molecular docking studies. Arch Pharm 357:e2300682. https:\/\/doi.org\/10.1002\/ardp.202300682","journal-title":"Arch Pharm"},{"key":"11561_CR33","doi-asserted-by":"publisher","first-page":"978","DOI":"10.3390\/molecules28030978","volume":"28","author":"AM Alsibaee","year":"2023","unstructured":"Alsibaee AM, Al-Yousef HM, Al-Salem HS (2023) Quinazolinones, the winning horse in drug discovery. Molecules 28:978. https:\/\/doi.org\/10.3390\/molecules28030978","journal-title":"Molecules"},{"key":"11561_CR34","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1007\/978-1-4939-2269-7_19","volume-title":"Chemical Biology","author":"S Dallakyan","year":"2015","unstructured":"Dallakyan S, Olson AJ (2015) Small-Molecule Library Screening by Docking with PyRx. In: Hempel JE, Williams CH, Hong CC (eds) Chemical Biology. Springer, New York, New York, NY, pp 243\u2013250"},{"key":"11561_CR35","doi-asserted-by":"publisher","first-page":"42717","DOI":"10.1038\/srep42717","volume":"7","author":"A Daina","year":"2017","unstructured":"Daina A, Michielin O, Zoete V (2017) SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules. Sci Rep 7:42717. https:\/\/doi.org\/10.1038\/srep42717","journal-title":"Sci Rep"},{"key":"11561_CR36","doi-asserted-by":"publisher","first-page":"W513","DOI":"10.1093\/nar\/gkae303","volume":"52","author":"P Banerjee","year":"2024","unstructured":"Banerjee P, Kemmler E, Dunkel M, Preissner R (2024) ProTox 3.0: a webserver for the prediction of toxicity of chemicals. Nucleic Acids Res 52:W513\u2013W520. https:\/\/doi.org\/10.1093\/nar\/gkae303","journal-title":"Nucleic Acids Res"},{"key":"11561_CR37","doi-asserted-by":"publisher","first-page":"e850","DOI":"10.1016\/j.clbc.2022.09.002","volume":"22","author":"J Singh","year":"2022","unstructured":"Singh J, Sangwan N, Chauhan A, Avti PK (2022) Integrative expression, survival analysis and cellular miR-2909 molecular interplay in MRN complex check point sensor genes (MRN-CSG) involved in breast cancer. Clin Breast Cancer 22:e850\u2013e862. https:\/\/doi.org\/10.1016\/j.clbc.2022.09.002","journal-title":"Clin Breast Cancer"},{"key":"11561_CR38","doi-asserted-by":"publisher","first-page":"4574","DOI":"10.3390\/ijms20184574","volume":"20","author":"PHM Torres","year":"2019","unstructured":"Torres PHM, Sodero ACR, Jofily P, Silva-Jr FP (2019) Key topics in molecular docking for drug design. IJMS 20:4574. https:\/\/doi.org\/10.3390\/ijms20184574","journal-title":"IJMS"},{"key":"11561_CR39","doi-asserted-by":"publisher","first-page":"120","DOI":"10.5306\/wjco.v8.i2.120","volume":"8","author":"V Masoud","year":"2017","unstructured":"Masoud V, Pag\u00e8s G (2017) Targeted therapies in breast cancer: new challenges to fight against resistance. WJCO 8:120. https:\/\/doi.org\/10.5306\/wjco.v8.i2.120","journal-title":"WJCO"},{"key":"11561_CR40","doi-asserted-by":"publisher","DOI":"10.3892\/ol.2018.8304","author":"B Israel","year":"2018","unstructured":"Israel B, Tilghman S, Parker-Lemieux K, Payton-Stewart F (2018) Phytochemicals: current strategies for treating breast cancer (Review). Oncol Lett. https:\/\/doi.org\/10.3892\/ol.2018.8304","journal-title":"Oncol Lett"},{"key":"11561_CR41","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1186\/s13058-015-0560-9","volume":"17","author":"A Toss","year":"2015","unstructured":"Toss A, Cristofanilli M (2015) Molecular characterization and targeted therapeutic approaches in breast cancer. Breast Cancer Res 17:60. https:\/\/doi.org\/10.1186\/s13058-015-0560-9","journal-title":"Breast Cancer Res"},{"key":"11561_CR42","doi-asserted-by":"publisher","first-page":"29714","DOI":"10.1039\/C8RA04879G","volume":"8","author":"M Younas","year":"2018","unstructured":"Younas M, Hano C, Giglioli-Guivarc\u2019h N, Abbasi BH (2018) Mechanistic evaluation of phytochemicals in breast cancer remedy: current understanding and future perspectives. RSC Adv 8:29714\u201329744. https:\/\/doi.org\/10.1039\/C8RA04879G","journal-title":"RSC Adv"},{"key":"11561_CR43","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1186\/s12964-024-01607-9","volume":"22","author":"A Doostmohammadi","year":"2024","unstructured":"Doostmohammadi A, Jooya H, Ghorbanian K et al (2024) Potentials and future perspectives of multi-target drugs in cancer treatment: the next generation anti-cancer agents. Cell Commun Signal 22:228. https:\/\/doi.org\/10.1186\/s12964-024-01607-9","journal-title":"Cell Commun Signal"},{"key":"11561_CR44","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13058-019-1178-0","volume":"22","author":"IR Macpherson","year":"2020","unstructured":"Macpherson IR, Spiliopoulou P, Rafii S et al (2020) A phase I\/II study of epertinib plus trastuzumab with or without chemotherapy in patients with HER2\u2009\u2212\u2009positive metastatic breast cancer. Breast Cancer Res 22:1. https:\/\/doi.org\/10.1186\/s13058-019-1178-0","journal-title":"Breast Cancer Res"},{"key":"11561_CR45","doi-asserted-by":"publisher","first-page":"1978","DOI":"10.1158\/1535-7163.MCT-11-0730","volume":"11","author":"O Kalous","year":"2012","unstructured":"Kalous O, Conklin D, Desai AJ et al (2012) Dacomitinib (PF-00299804), an irreversible Pan-HER inhibitor, inhibits proliferation of HER2\u2009\u2212\u2009amplified breast cancer cell lines resistant to trastuzumab and lapatinib. Mol Cancer Ther 11:1978\u20131987. https:\/\/doi.org\/10.1158\/1535-7163.MCT-11-0730","journal-title":"Mol Cancer Ther"},{"key":"11561_CR46","doi-asserted-by":"publisher","first-page":"557","DOI":"10.7150\/jca.6689","volume":"4","author":"A Nakayama","year":"2013","unstructured":"Nakayama A, Takagi S, Yusa T et al (2013) Antitumor activity of TAK-285, an investigational, non-Pgp substrate HER2\/EGFR kinase inhibitor, in cultured tumor cells, mouse and rat xenograft tumors, and in an HER2\u2009\u2212\u2009positive brain metastasis model. J Cancer 4:557\u2013565. https:\/\/doi.org\/10.7150\/jca.6689","journal-title":"J Cancer"},{"key":"11561_CR47","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1038\/bjc.2011.590","volume":"106","author":"T Doi","year":"2012","unstructured":"Doi T, Takiuchi H, Ohtsu A et al (2012) Phase I first-in-human study of TAK-285, a novel investigational dual HER2\/EGFR inhibitor, in cancer patients. Br J Cancer 106:666\u2013672. https:\/\/doi.org\/10.1038\/bjc.2011.590","journal-title":"Br J Cancer"},{"key":"11561_CR48","doi-asserted-by":"publisher","first-page":"327","DOI":"10.5732\/cjc.010.10507","volume":"30","author":"B-H Xu","year":"2011","unstructured":"Xu B-H, Jiang Z-F, Chua D et al (2011) Lapatinib plus capecitabine in treating HER2\u2009\u2212\u2009positive advanced breast cancer: efficacy, safety, and biomarker results from Chinese patients. Chin J Cancer 30:327\u2013335. https:\/\/doi.org\/10.5732\/cjc.010.10507","journal-title":"Chin J Cancer"},{"key":"11561_CR49","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1517\/13543784.2014.924505","volume":"23","author":"SA Hurvitz","year":"2014","unstructured":"Hurvitz SA, Shatsky R, Harbeck N (2014) Afatinib in the treatment of breast cancer. Expert Opin Investig Drugs 23:1039\u20131047. https:\/\/doi.org\/10.1517\/13543784.2014.924505","journal-title":"Expert Opin Investig Drugs"},{"key":"11561_CR50","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.clbc.2014.11.004","volume":"15","author":"MF Rimawi","year":"2015","unstructured":"Rimawi MF, Aleixo SB, Rozas AA et al (2015) A neoadjuvant, randomized, open-label phase II trial of afatinib versus trastuzumab versus lapatinib in patients with locally advanced HER2\u2009\u2212\u2009positive breast cancer. Clin Breast Cancer 15:101\u2013109. https:\/\/doi.org\/10.1016\/j.clbc.2014.11.004","journal-title":"Clin Breast Cancer"},{"key":"11561_CR51","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1186\/s12885-022-10428-3","volume":"23","author":"Y Harada","year":"2023","unstructured":"Harada Y, Sato A, Nakamura H et al (2023) Anti-cancer effect of afatinib, dual inhibitor of HER2 and EGFR, on novel mutation HER2 E401G in models of patient-derived cancer. BMC Cancer 23:77. https:\/\/doi.org\/10.1186\/s12885-022-10428-3","journal-title":"BMC Cancer"},{"key":"11561_CR52","doi-asserted-by":"publisher","first-page":"2502","DOI":"10.3390\/cancers12092502","volume":"12","author":"YV Ashar","year":"2020","unstructured":"Ashar YV, Zhou J, Gupta P et al (2020) BMS-599626, a highly selective Pan-HER kinase inhibitor, antagonizes ABCG2-mediated drug resistance. Cancers 12:2502. https:\/\/doi.org\/10.3390\/cancers12092502","journal-title":"Cancers"},{"key":"11561_CR53","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2018\/7628734","volume":"2018","author":"HAM Gomaa","year":"2018","unstructured":"Gomaa HAM, Ali AT, Gabbar MA, Kandeil MA (2018) The effect of canertinib on sensitivity of cytotoxic drugs in tamoxifen-resistant breast cancer cells in vitro. Int J Genom 2018:1\u201310. https:\/\/doi.org\/10.1155\/2018\/7628734","journal-title":"Int J Genom"},{"key":"11561_CR54","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.toxlet.2023.07.011","volume":"384","author":"S Gould","year":"2023","unstructured":"Gould S, Templin MV (2023) Off target toxicities and links with physicochemical properties of medicinal products, including antibiotics, oligonucleotides, lipid nanoparticles (with cationic and\/or anionic charges). Data review suggests an emerging pattern. Toxicol Lett 384:14\u201329. https:\/\/doi.org\/10.1016\/j.toxlet.2023.07.011","journal-title":"Toxicol Lett"},{"issue":"2","key":"11561_CR55","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/j.bbagen.2005.12.017","volume":"1760","author":"KL Khanduja","year":"2006","unstructured":"Khanduja KL, Avti PK, Kumar S, Mittal N, Sohi KK, Pathak CM (2006) Anti-apoptotic activity of caffeic acid, ellagic acid and ferulic acid in normal human peripheral blood mononuclear cells. Biochimi Biophys Acta 1760(2):283\u2013289. https:\/\/doi.org\/10.1016\/j.bbagen.2005.12.017","journal-title":"Biochimi Biophys Acta"},{"key":"11561_CR56","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1146\/annurev.arplant.55.031903.141701","volume":"55","author":"K Apel","year":"2004","unstructured":"Apel K, Hirt H (2004) Reactive oxygen species: metabolism, oxidative stress, and signal transduction. Annu Rev Plant Biol 55:373\u2013399. https:\/\/doi.org\/10.1146\/annurev.arplant.55.031903.141701","journal-title":"Annu Rev Plant Biol"},{"key":"11561_CR57","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1038\/s41571-020-0341-y","volume":"17","author":"BA Carneiro","year":"2020","unstructured":"Carneiro BA, El-Deiry WS (2020) Targeting apoptosis in cancer therapy. Nat Rev Clin Oncol 17:395\u2013417. https:\/\/doi.org\/10.1038\/s41571-020-0341-y","journal-title":"Nat Rev Clin Oncol"}],"container-title":["Molecular Diversity"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11030-026-11561-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11030-026-11561-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11030-026-11561-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T13:47:42Z","timestamp":1791121662000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11030-026-11561-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,9]]},"references-count":57,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026,10]]}},"alternative-id":["11561"],"URL":"https:\/\/doi.org\/10.1007\/s11030-026-11561-y","relation":{},"ISSN":["1573-501X"],"issn-type":[{"value":"1573-501X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,9]]},"assertion":[{"value":"19 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All the authors declare no conflict of interest. All the authors declare no conflicts of financial or personal interest that could have influenced this study.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}}]}}